Metabolism of new-generation taxanes in human, pig, minipig and rat liver microsomes

Xenobiotica

Volumn 36, Issue 9, 2006, Pages 772-792

  Gut, I ^a   Ojima, I ^b   Vaclavikova, R ^c   Simek, P ^d   Horsky, S ^a   Linhart, I ^e   Soucek, P ^a   Kondrova, E ^a   Kuznetsova, L V ^b   Chen, J ^b  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^b STONY BROOK UNIVERSITY   (United States)

^c CHARLES UNIVERSITY   (Czech Republic)

^d INSTITUTE OF MATHEMATICS   (Czech Republic)

^e INSTITUTE OF CHEMICAL TECHNOLOGY   (Czech Republic)

Author keywords

CYP3A orthologues; Cytochrome P450 (CYP); Human metabolism; Novel taxanes; Species differences; Tandem mass spectrometry (MS MS)

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A6; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DOCETAXEL; DRUG METABOLITE; PACLITAXEL; SB T 1102; SB T 1214; SB T 1216; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; LIVER MICROSOME; MALE; MINIPIG; NONHUMAN; PROTEIN EXPRESSION; RAT; SWINE; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; HUMANS; MALE; MICROSOMES, LIVER; RATS; RATS, WISTAR; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SWINE; SWINE, MINIATURE; TAXOIDS;

SUS SCROFA;

EID: 33748711014     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250600829220     Document Type: Article

References (21)

1. Brooks T, Minderman H, O'Loughlin KL, Pera P, Ojima I, Baer MR, Bernacki RJ. 2003. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Molecular Cancer Therapeutics 2:1195-1205.
2. Ehrlichova M, Vaclaviková R, Ojima I, Wu X, Kuznetsova LV, Chen J, Truksa J, Souček P, Kovar J, Gut I. 2005. Transport and cytotoxicity of paclitaxel, docetaxel and three novel taxanes in human breast cancer cells. Naunyn-Schmiedeberg's Archives of Pharmacology 372:95-105.
3. Ferlini C, Distefano M, Pignaletti F, Lin S, Riva A, Bombardelli E, Mancuso S, Ojima I, Scambia G. 2000. Antitumor activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors. British Journal of Cancer 83:1762-1768.
4. Geney R, Ungureanu M, Li D, Ojima I. 2002. Overcoming multidrug resistance in taxane chemotherapy. Clinical Chemistry and Laboratory Medicine 40:918-925.
5. Gottesman MM, Pastan I. 1993. Modulation of multidrug resistance phenotype. Cellular Pharmacology 1:S111-S112.
6. Gut I, Danielová V, Holubová J, Souček P, Klučková H. 2000. Cytotoxicity of cyclophosphamide, paclitaxel and docetaxel for tumor cell lines in vitro: Effects of concentration, time and CYP-catalysed metabolism. Archives in Toxicology 74:437-446.
7. Huizing MT, Sewberath Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, Pinedo HM, Beijnen JH. 1995. Taxanes: A new class of antitumor agents. Cancer Investigation 13:381-404.
8. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 193:265-275.
9. Miller ML, Ojima I. 2001. Chemistry and chemical biology of taxane anticancer agents. Chemical Record 1:195-211.
10. Nedelcheva V, Gut I. 1994. Cytochromes P450 in rats and humans: Methods of investigation, substrate specificities and relevance to cancer. Xenobiotica 24:1151-1175.
11. Nedelcheva V, Gut I, Souček P, Frantik E. 1998. Cytochrome P450 catalysed oxidation of monochlorobenzene, 1,2- and 1,4-dichlorobenzene in rat, mouse and human liver microsomes. Chemical and Biological Interactions 115:53-70.
12. Nedelcheva V, Gut I, Souček P, Tichavska B, Tynkova L, Mraz J, Guengerich FP, Ingelman-Sundberg M. 1999. Metabolism of benzene in human liver microsomes: Individual variations in relation to CYP2E1 expression. Archives of Toxicology 73:33-40.
13. Ojima I. 2000. Taxoid anti-tumor agents and pharmaceutical compositions thereof. US Patent No. 6,100,411.
14. Ojima I, Slater JC, Michaud E, Kuduk SD, Bounaud PY, Vrignaud P, Bissery MC, Veith JM, Pera P, Bernacki RJ. 1996. Synthesis and structure-activity relationships of the second-generation antitumor taxoids: Exceptional activity against drug-resistant cancer cells. Journal of Medicinal Chemistry 39:3889-3896.
15. Ojima I, Wang T, Miller ML, Lin S, Borella CP, Geng X, Pera P, Bernacki RJ. 1999. Synthesis and structure-activity relationships of new second-generation taxoids. Bioorganic and Medicinal Chemistry Letters 9:3423-3428.
16. Omura T, Sato R. 1964. The carbon monoxide-binding pigment of liver microsomes: Evidence for its haemoprotein nature. Journal of Biological Chemistry 239:2370-2378.
17. Parikh A, Gillam EM, Guengerich FP. 1997. Drug metabolism by Escherichia coli expressing human cytochromes P450. Nature Biotechnology 15:784-788.
18. Rahman A, Korzekwa KR, Grogan J, Gonzalez J, Harris JW. 1994. Selective biotransformation of Taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Research 54:5543-5546.
19. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. 1992. Taxol: The first of the taxanes, an important new class of antitumor agents. Seminars in Oncology 19:646-662.
20. Souček P, Gut I. 1992. Cytochrome P450 forms in rats: Structures, functions and relevant human forms. Xenobiotica 22:83-103.
21. Vaclaviková R, Soucek P, Svobodova L, Anzenbacher P, Simek P, Guengerich FP, Gut I. 2004. Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, minipigs and regular pigs. Drug Metabolism and Disposition 32:666-674.